

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Everest Medicines Limited (the “**Company**”) is pleased to announce that Ms. Lan Kang (“**Ms. Kang**”) has been appointed as a non-executive Director of the Company with effect from December 22, 2020.

The biographical details of Ms. Kang are set out below:

Ms. Kang, aged 51, has served at Fosun in multiple roles from 2010 to 2019, including as Executive Board Director and Senior Vice President of Fosun International, responsible for Fosun’s insurance business, as well as chief HR officer at Fosun. She also held the role of non-executive Board Director at a number of healthcare related companies, including Fosun Pharma and Fosun United Health Insurance. Prior to joining Fosun, Ms. Kang spent five years at McKinsey & Company in China, in addition to working as an oncology research scientist in her early career. She is currently a managing director at C-Bridge Value Creation Limited of CBC Group.

Ms. Kang was a non-executive director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX.2196) from June 2013 to March 2018 and an executive director of Fosun International Limited (HKEX.0656) from March 2017 to November 2018.

Ms. Kang obtained her Bachelor’s degree in Biological Science and Technology from Zhejiang University in China, her MBA degree in Healthcare Management from The Wharton School of the University of Pennsylvania, and her Master’s degree in Biochemistry from Tulane University, Louisiana, USA.

Ms. Kang has entered into an appointment letter with the Company for a term of three years commencing from December 22, 2020, subject to (i) retirement from office and re-election at the next general meeting of the Company and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”). According to the terms of Ms. Kang’s appointment, Ms. Kang will not receive any remuneration and benefits

in her capacity as a non-executive Director and Ms. Kang is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of her duties in connection with the business of the Company.

Save as disclosed above, as at the date of this announcement, Ms. Kang has confirmed that she does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

Save as disclosed above, as at the date of this announcement, Ms. Kang has confirmed that she does not have any relationship with any Director, senior management or substantial shareholder or controlling shareholder of the Company, or any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange relating to Ms. Kang's appointment.

The Board would like to express its warmest welcome to Ms. Kang on her appointment.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, December 22, 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.